SYNRIBO® (Omacetaxine mepesuccinate)

The FDA on October 26, 2012 granted accelerated approval to SYNRIBO® for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKIs). SYNRIBO® is administered as a subcutaneous injection and is a product of Teva Pharmaceutical Industries Ltd.